Hannah Tapsell Chapman
Venture Capital Investor @ Mercia’s EIS funds
Hannah Tapsell Chapman is a seed investor at Mercia’s EIS funds focused on Biotechnology and EdTech. Hannah Tapsell Chapman is the Investment Manager at Mercia Asset Management PLC.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Hannah Tapsell Chapman invests in
Stages Hannah Tapsell Chapman invests in
Countries Hannah Tapsell Chapman invests in
Investment Focus
Industry
- Biotechnology 2 (33%)
- EdTech 1 (17%)
- Genetics 1 (17%)
- Training 1 (17%)
- E-Learning 1 (17%)
Stage
- Seed 3 (50%)
- Venture - Series Unknown 2 (33%)
- Funding Round 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NuVision
|
NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at theUniversity of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham. | $6.5M / Venture - Series Unknown / Feb 05, 2026 | |
Forge Genetics
|
Forge Genetics is a startup with proprietary Forge Editing technology, bypassing CRISPR patents for precision gene-editing services. | $2.7M / Seed / Oct 01, 2025 | |
Graide
|
Graide is a feedback platform that provides insight to learn and avoid feedback. | $2.1M / Venture - Series Unknown / Feb 27, 2024 | |
IsomAb
|
IsomAb evaluate and develop isoform specific antibodies to treat disease. | $9.5M / Seed / Feb 20, 2024 | |
ImmuONE
|
ImmuONE provides solutions for inhalation toxicology, irritation sensitization, alveolar clearance, and inflammation. If you want would contact them please contact them via phone call or email. | Oct 25, 2023 | |
|
ImmuONE
|
ImmuONE provides solutions for inhalation toxicology, irritation sensitization, alveolar clearance, and inflammation. If you want would contact them please contact them via phone call or email. | $2.4M / Seed / Oct 25, 2023 |
Co-Investors
About Mercia’s EIS funds
Mercia’s EIS funds
Mercia’s EIS funds Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Hannah Tapsell Chapman
Venture Capital Investor
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Hannah Tapsell Chapman invest in?
Hannah Tapsell Chapman invests primarily in Biotechnology, EdTech and Genetics startups, most often at Seed and Venture - Series Unknown stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Hannah Tapsell Chapman last invest?
The most recent investment recorded for Hannah Tapsell Chapman closed in Feb 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
